Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 5/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5001579 | 0.97 | SRD5A2 (0.39) | SRD5A2SRD5A1PDK2ALDH1A1TTR | |
| SCHEMBL5001581 | 0.86 | PDK2 (0.33) | PDK2 | |
| SCHEMBL8234379 | 0.83 | BACE1 (0.45) | CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL5001534 | 0.81 | BACE1 (0.43) | CYP2C9 | |
| SCHEMBL14010655 | 0.81 | NOS3 (0.38) | ALDH1A1CYP2C9KDM4EMAPT | |
| SCHEMBL8240599 | 0.80 | PDK2 (0.40) | PDK2 | |
| Trifluoroacetic Acid SCHEMBL5001889 | 0.79 | PARP1 (0.37) | SRD5A2SRD5A1PDK2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5002152 | 0.79 | PDK2 (0.40) | PDK2 | |
| SCHEMBL14010667 | 0.79 | PDK2 (0.48) | PDK2 | |
| Trifluoroacetic Acid SCHEMBL5005103 | 0.76 | PDK2 (0.46) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957462-A2 | NOVEL 2-AMINO-HETEROCYCLES UDEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | Astra Zeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | SRD5A2 3088/4885SRD5A1 3248/4885PDK2 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.